Reshaping Australian drug policy: The dilemmas of generic medicines policy

Australia and New Zealand Health Policy

Volumn 4, Issue 1, 2007, Pages

  Löfgren, Hans ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AUSTRALIA; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; EXPIRATION DATE; GOVERNMENT REGULATION; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HUMAN; HYPERCHOLESTEROLEMIA; NOTE; PATENT; PHARMACEUTICAL CARE; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 34347234774     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-4-11     Document Type: Note

References (17)

1. Frederick J Trading Blows, Target and Wal-mart Roll out $4 Generic Offers Nationwide Drug News Store 2006
2. Abbott T Transcrip Press Conference: PBS Reform 2006
3. Department of Health and Ageing New Pricing and Listing Arrangements for Generic Medicines on the Pharmaceutical Benefits Scheme (PBS) http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-pricereductions/$FILE/qamar05.pdf
4. Davey P Strategic Management: Pharmaceutical generics A Changing Playing Field 4th Annual Pharma Marketing & Sales Congress, 3-4 May
5. Genepharm Australasia Annual Report 2006 http://www.genepharm.com.au/ investors/news.php
6. Pharmaceutical Benefits Pricing Authority Annual Report for the Year ended 30 June 2006 Canberra, Department of Health and Ageing 2006
7. Lopez-Casanovas G Puig-Junoy J Review of the Literature on Reference Pricing Health Policy 2000 54 87-123 10.1016/S0168-8510(00)00100-7 11094265
8. Ioannides-Demos LL Ibrahim JE McNeil JJ Reference-Based Pricing Schemes: Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes Pharmacoeconomics 2002 20 577-591 10.2165/ 00019053-200220090-00002 12141886
9. Department of Health and Ageing Questions and Answers: Price Change of Atorvastin (Lipitor) in the 1 August Issue of the Schedule of Pharmaceutical Benefits http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/health-pbs-atorvastinqa#
10. Department of Health and Ageing Strengthening Your PBS: Preparing for the Future http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ Strengthening-your-PBS.htm
11. Hollis A How Do Brands' "Own Generics" Affect Pharmaceutical Prices? Review of Industrial Organization 2005 27 329-350 10.1007/ s11151-005-5469-5
12. Probyn A Some Drugs More Equal Than Others: Pseudo-generics and Commercial Practice Australian Health Review 2004 28 207-217 15527401
13. Thomas JR Authorized Generic Pharmaceuticals: Effects on Innovation http://digital.library.unt.edu/govdocs/crs//data/2006/upl-meta-crs-9508/ RL33605_2006Aug08.pdf?PHPSESSID=66b9668fc6c02942c76df2dfdb8a8968
14. Grattan M Stafford A US Drug Companies Eye Australia The Age Melbourne, 2006 2
15. Faunce T Doran E Henry D Drahos P Pekarsky B Neville W Searles A Assessing the Impact of the Australia-United States Free Trade Agreement on Australian and Global Medicines Policy Globalization and Health 2005 1
16. Metherell M Patients to Receive a Sugar-Coated Pill Sydney Morning Herald Sydney 2006 1
17. Mitchell A Chemists Limit PBS Reform Australian Financial Review 2006 58